COL18A1 and non-small cell lung carcinoma: Therefore, larger sample sizes, multicenter, randomized, and controlled clinical trials are warranted to provide further validation for the use of rh‐endostatin and camrelizumab treating advanced NSCLC, as well as to confirm its long‐term efficacy and toxicity.